Diabetes drug Byetta shows no increase in CV risk
This article was originally published in Scrip
Executive Summary
Lilly/Amylin's injectable type 2 diabetes drug Byetta (exenatide) shows no increase in cardiovascular risk, the companies concluded after performing a meta-analysis across their clinical trials database of the first-in-class GLP-1 analogue.